Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

  • Jacek Hajda1Email authorView ORCID ID profile,
  • Monika Lehmann1,
  • Ottheinz Krebs2,
  • Meinhard Kieser3,
  • Karsten Geletneky4,
  • Dirk Jäger5,
  • Michael Dahm2,
  • Bernard Huber2,
  • Tilman Schöning6,
  • Oliver Sedlaczek7,
  • Albrecht Stenzinger8,
  • Niels Halama9,
  • Volker Daniel10,
  • Barbara Leuchs11,
  • Assia Angelova11,
  • Jean Rommelaere11,
  • Christine E. Engeland5,
  • Christoph Springfeld5 and
  • Guy Ungerechts5
Contributed equally
BMC Cancer201717:576

https://doi.org/10.1186/s12885-017-3604-y

Received: 22 April 2016

Accepted: 24 August 2017

Published: 29 August 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
22 Apr 2016 Submitted Original manuscript
18 Jul 2016 Author responded Author comments - Jacek Hajda
Resubmission - Version 2
18 Jul 2016 Submitted Manuscript version 2
2 Jan 2017 Reviewed Reviewer Report - Jean Baptiste Bachet
20 Feb 2017 Reviewed Reviewer Report - Anne M Noonan
27 Mar 2017 Author responded Author comments - Jacek Hajda
Resubmission - Version 3
27 Mar 2017 Submitted Manuscript version 3
3 Apr 2017 Reviewed Reviewer Report - Anne M Noonan
26 Jun 2017 Author responded Author comments - Jacek Hajda
Resubmission - Version 4
26 Jun 2017 Submitted Manuscript version 4
Publishing
24 Aug 2017 Editorially accepted
29 Aug 2017 Article published 10.1186/s12885-017-3604-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Coordination Centre for Clinical Trials, University Hospital Heidelberg, Marsilius-Arkaden, Tower West
(2)
Oryx GmbH & Co KG
(3)
Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Marsilius-Arkaden, Tower West
(4)
Department of Neurosurgery, Klinikum Darmstadt
(5)
Department of Medical Oncology, National Center for Tumor Diseases (NCT)
(6)
Central Pharmacy, University Hospital Heidelberg
(7)
Department of Radiology, German Cancer Research Center
(8)
Department of Pathology, University Hospital Heidelberg
(9)
Tissue Imaging & Analysis Center (TIGA), University Heidelberg – BioQuant
(10)
Institute of Immunology, Transplantation Immunology, University Hospital Heidelberg
(11)
Department of Applied Tumor Virology, German Cancer Research Center

Advertisement